Cetuximab, first described inhibiting EGFR in 1988 [10], was accepted for clinical use in the KRAS wild-type colorectal cancer (CRC) treatment, leading to the first routine genotyping of CRC patients, since somatic mutations of KRAS were found to confer cetuximab resistance [11]. This evidence concerns the gene KRAS and colorectal carcinoma.